Clinical significance of the lymphocyte-to-monocyte ratio in multiple myeloma patients with negative minimal residual disease: a single-center retrospective analysis View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2021-08-02

AUTHORS

Kazuhito Suzuki, Kaichi Nishiwaki, Riku Nagao, Mitsuji Katori, Ryoko Fukushima, Daiki Hattori, Hidekazu Masuoka, Shingo Yano

ABSTRACT

Minimal residual disease (MRD) is a surrogate marker for survival in multiple myeloma (MM), while the lymphocyte-to-monocyte ratio (LMR) is a prognostic factor associated with the patients’ immunological status. We retrospectively evaluated the clinical impact of MRD negativity and LMR. MRD was analyzed by multicolor flowcytometry (threshold, 1 × 10–5). Fifty-eight patients (median age 70 years) who achieved complete response were included in this study. Twenty-two patients received autologous stem cell transplantation, 14 received daratumumab-based chemotherapy, and 22 received another treatment. Forty-one (70.7%) patients achieved MRD negativity. Over the median follow-up time of 15.1 months, PFS in MRD-negative patients was significantly longer than in MRD-positive patients (P = 0.020). In addition, a high LMR at MRD assessment was associated with MRD negativity (P = 0.019) and long PFS (P = 0.009). Finally, neither MRD negativity nor high LMR at MRD assessment was associated with significantly shorter PFS compared with MRD positivity or low LMR (P = 0.002). In conclusion, high LMR was associated with MRD negativity and can be used as a predictor of long PFS. Change of treatment strategy might be essential for patients with MRD positivity and high LMR at MRD assessment due to their short PFS. More... »

PAGES

599-607

References to SciGraph publications

  • 2017-12-15. The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents in BLOOD CANCER JOURNAL
  • 2021-04. MRD Assessment in Multiple Myeloma: Progress and Challenges in CURRENT HEMATOLOGIC MALIGNANCY REPORTS
  • 2019-02-18. Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry in INTERNATIONAL JOURNAL OF HEMATOLOGY
  • 2019-09-16. Combined immune score of lymphocyte to monocyte ratio and immunoglobulin levels predicts treatment-free survival of multiple myeloma patients after autologous stem cell transplant in BONE MARROW TRANSPLANTATION
  • 2006-05-17. Early lymphocyte recovery predicts longer survival after autologous peripheral blood stem cell transplantation in multiple myeloma in BONE MARROW TRANSPLANTATION
  • 2018-06-20. Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials in LEUKEMIA
  • 2012-12-03. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics in BONE MARROW TRANSPLANTATION
  • 2006-09-15. Competence and competition: the challenge of becoming a long-lived plasma cell in NATURE REVIEWS IMMUNOLOGY
  • <error retrieving object. in <ERROR RETRIEVING OBJECT
  • 2011-01-21. Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma in LEUKEMIA
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s12185-021-03201-y

    DOI

    http://dx.doi.org/10.1007/s12185-021-03201-y

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1140125322

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/34339005


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged, 80 and over", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Biomarkers", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Biomarkers, Tumor", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Disease Management", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Disease Susceptibility", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Leukocyte Count", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Lymphocyte Count", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Lymphocytes", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Monocytes", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Multiple Myeloma", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Neoplasm, Residual", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Prognosis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Retrospective Studies", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "The Jikei University School of Medicine, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/grid.411898.d", 
              "name": [
                "Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University Kashiwa Hospital, 163-1 Kashiwa-shita, 277-8567, Kashiwa, Chiba, Japan", 
                "The Jikei University School of Medicine, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Suzuki", 
            "givenName": "Kazuhito", 
            "id": "sg:person.01237063604.97", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01237063604.97"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "The Jikei University School of Medicine, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/grid.411898.d", 
              "name": [
                "Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University Kashiwa Hospital, 163-1 Kashiwa-shita, 277-8567, Kashiwa, Chiba, Japan", 
                "The Jikei University School of Medicine, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Nishiwaki", 
            "givenName": "Kaichi", 
            "id": "sg:person.01016710710.32", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01016710710.32"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "The Jikei University School of Medicine, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/grid.411898.d", 
              "name": [
                "Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University Kashiwa Hospital, 163-1 Kashiwa-shita, 277-8567, Kashiwa, Chiba, Japan", 
                "The Jikei University School of Medicine, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Nagao", 
            "givenName": "Riku", 
            "id": "sg:person.015357612447.65", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015357612447.65"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "The Jikei University School of Medicine, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/grid.411898.d", 
              "name": [
                "Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University Kashiwa Hospital, 163-1 Kashiwa-shita, 277-8567, Kashiwa, Chiba, Japan", 
                "The Jikei University School of Medicine, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Katori", 
            "givenName": "Mitsuji", 
            "id": "sg:person.014735732441.34", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014735732441.34"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "The Jikei University School of Medicine, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/grid.411898.d", 
              "name": [
                "Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University Kashiwa Hospital, 163-1 Kashiwa-shita, 277-8567, Kashiwa, Chiba, Japan", 
                "The Jikei University School of Medicine, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Fukushima", 
            "givenName": "Ryoko", 
            "id": "sg:person.011347513173.04", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011347513173.04"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "The Jikei University School of Medicine, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/grid.411898.d", 
              "name": [
                "Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University Kashiwa Hospital, 163-1 Kashiwa-shita, 277-8567, Kashiwa, Chiba, Japan", 
                "The Jikei University School of Medicine, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Hattori", 
            "givenName": "Daiki", 
            "id": "sg:person.016103216547.04", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016103216547.04"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "The Jikei University School of Medicine, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/grid.411898.d", 
              "name": [
                "Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University Kashiwa Hospital, 163-1 Kashiwa-shita, 277-8567, Kashiwa, Chiba, Japan", 
                "The Jikei University School of Medicine, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Masuoka", 
            "givenName": "Hidekazu", 
            "id": "sg:person.01065024110.36", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065024110.36"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "The Jikei University School of Medicine, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/grid.411898.d", 
              "name": [
                "The Jikei University School of Medicine, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Yano", 
            "givenName": "Shingo", 
            "id": "sg:person.01265010246.42", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01265010246.42"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/sj.bmt.1705373", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047732682", 
              "https://doi.org/10.1038/sj.bmt.1705373"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s11899-021-00633-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1137751851", 
              "https://doi.org/10.1007/s11899-021-00633-5"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/leu.2010.320", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1024484528", 
              "https://doi.org/10.1038/leu.2010.320"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s12185-019-02615-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1112212201", 
              "https://doi.org/10.1007/s12185-019-02615-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bcj.2017.60", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1090295330", 
              "https://doi.org/10.1038/bcj.2017.60"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41375-018-0163-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1104990592", 
              "https://doi.org/10.1038/s41375-018-0163-4"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bmt.2012.244", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028358194", 
              "https://doi.org/10.1038/bmt.2012.244"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41409-019-0681-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1121007421", 
              "https://doi.org/10.1038/s41409-019-0681-3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nri1886", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004152575", 
              "https://doi.org/10.1038/nri1886"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41408-017-0019-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1099676148", 
              "https://doi.org/10.1038/s41408-017-0019-6"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2021-08-02", 
        "datePublishedReg": "2021-08-02", 
        "description": "Minimal residual disease (MRD) is a surrogate marker for survival in multiple myeloma (MM), while the lymphocyte-to-monocyte ratio (LMR) is a prognostic factor associated with the patients\u2019 immunological status. We retrospectively evaluated the clinical impact of MRD negativity and LMR. MRD was analyzed by multicolor flowcytometry (threshold, 1\u2009\u00d7\u200910\u20135). Fifty-eight patients (median age 70\u00a0years) who achieved complete response were included in this study. Twenty-two patients received autologous stem cell transplantation, 14 received daratumumab-based chemotherapy, and 22 received another treatment. Forty-one (70.7%) patients achieved MRD negativity. Over the median follow-up time of 15.1\u00a0months, PFS in MRD-negative patients was significantly longer than in MRD-positive patients (P\u2009=\u20090.020). In addition, a high LMR at MRD assessment was associated with MRD negativity (P\u2009=\u20090.019) and long PFS (P\u2009=\u20090.009). Finally, neither MRD negativity nor high LMR at MRD assessment was associated with significantly shorter PFS compared with MRD positivity or low LMR (P\u2009=\u20090.002). In conclusion, high LMR was associated with MRD negativity and can be used as a predictor of long PFS. Change of treatment strategy might be essential for patients with MRD positivity and high LMR at MRD assessment due to their short PFS.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s12185-021-03201-y", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1076985", 
            "issn": [
              "0925-5710", 
              "1865-3774"
            ], 
            "name": "International Journal of Hematology", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "5", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "114"
          }
        ], 
        "keywords": [
          "minimal residual disease", 
          "MRD negativity", 
          "high LMR", 
          "MRD assessment", 
          "monocyte ratio", 
          "longer PFS", 
          "MRD positivity", 
          "shorter PFS", 
          "residual disease", 
          "multiple myeloma", 
          "immunological status", 
          "autologous stem cell transplantation", 
          "single-center retrospective analysis", 
          "negative minimal residual disease", 
          "patient's immunological status", 
          "MRD-negative patients", 
          "MRD-positive patients", 
          "stem cell transplantation", 
          "multiple myeloma patients", 
          "multicolor flowcytometry", 
          "median follow", 
          "prognostic factors", 
          "complete response", 
          "low LMR", 
          "myeloma patients", 
          "cell transplantation", 
          "surrogate marker", 
          "treatment strategies", 
          "clinical impact", 
          "clinical significance", 
          "retrospective analysis", 
          "patients", 
          "PFS", 
          "LMR", 
          "lymphocytes", 
          "disease", 
          "positivity", 
          "negativity", 
          "chemotherapy", 
          "myeloma", 
          "transplantation", 
          "assessment", 
          "follow", 
          "flowcytometry", 
          "months", 
          "survival", 
          "treatment", 
          "predictors", 
          "markers", 
          "conclusion", 
          "status", 
          "response", 
          "factors", 
          "significance", 
          "study", 
          "ratio", 
          "changes", 
          "addition", 
          "strategies", 
          "impact", 
          "time", 
          "analysis"
        ], 
        "name": "Clinical significance of the lymphocyte-to-monocyte ratio in multiple myeloma patients with negative minimal residual disease: a single-center retrospective analysis", 
        "pagination": "599-607", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1140125322"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s12185-021-03201-y"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "34339005"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s12185-021-03201-y", 
          "https://app.dimensions.ai/details/publication/pub.1140125322"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-08-04T17:09", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_914.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s12185-021-03201-y"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12185-021-03201-y'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12185-021-03201-y'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12185-021-03201-y'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12185-021-03201-y'


     

    This table displays all metadata directly associated to this object as RDF triples.

    285 TRIPLES      21 PREDICATES      115 URIs      97 LITERALS      25 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s12185-021-03201-y schema:about N0422762378e349a688beb000b8b34413
    2 N1bf95e64d8204a04a1aa1dea5417e9f0
    3 N30ac29c02c504fb09d31a1d2bd365313
    4 N459b43d041574207b7d658167377e51f
    5 N4d79d4832993471793d34ebb86178186
    6 N59898e3769fa4a1a847f32726181f482
    7 N6698efdd38bd404082d1838481c551d7
    8 N952a0a32533747f6814ffe7ac4cf99ed
    9 Nac60dfc9ab0b4d518eda7d88dc1d75a9
    10 Nae4bfc3aefe9435ba634236a655f19ec
    11 Nb0f1ba2ee60b41e1b9550d3135c10afb
    12 Nc1b92b98958c4ffd9a3db28f8e0b38c1
    13 Nc2b4c2585d9b437caa2f4ab8124bb243
    14 Nc59b5a7bbeed49ea95efaa9e5cbadb36
    15 Nc8ff6521558b48549b524d8f27542b0e
    16 Nf1b4b763bb2b4c1bb3742b5be5004e13
    17 Nf32f5661ed164a6daf5fe1a761ba8c20
    18 Nfc3d2fb4bc3243d7af0355526f48fea7
    19 anzsrc-for:11
    20 anzsrc-for:1103
    21 schema:author N48bf56c423844ec88d897fcbe8fb46f9
    22 schema:citation sg:pub.10.1007/s11899-021-00633-5
    23 sg:pub.10.1007/s12185-019-02615-z
    24 sg:pub.10.1038/bcj.2017.60
    25 sg:pub.10.1038/bmt.2012.244
    26 sg:pub.10.1038/leu.2010.320
    27 sg:pub.10.1038/nri1886
    28 sg:pub.10.1038/s41375-018-0163-4
    29 sg:pub.10.1038/s41408-017-0019-6
    30 sg:pub.10.1038/s41409-019-0681-3
    31 sg:pub.10.1038/sj.bmt.1705373
    32 schema:datePublished 2021-08-02
    33 schema:datePublishedReg 2021-08-02
    34 schema:description Minimal residual disease (MRD) is a surrogate marker for survival in multiple myeloma (MM), while the lymphocyte-to-monocyte ratio (LMR) is a prognostic factor associated with the patients’ immunological status. We retrospectively evaluated the clinical impact of MRD negativity and LMR. MRD was analyzed by multicolor flowcytometry (threshold, 1 × 10–5). Fifty-eight patients (median age 70 years) who achieved complete response were included in this study. Twenty-two patients received autologous stem cell transplantation, 14 received daratumumab-based chemotherapy, and 22 received another treatment. Forty-one (70.7%) patients achieved MRD negativity. Over the median follow-up time of 15.1 months, PFS in MRD-negative patients was significantly longer than in MRD-positive patients (P = 0.020). In addition, a high LMR at MRD assessment was associated with MRD negativity (P = 0.019) and long PFS (P = 0.009). Finally, neither MRD negativity nor high LMR at MRD assessment was associated with significantly shorter PFS compared with MRD positivity or low LMR (P = 0.002). In conclusion, high LMR was associated with MRD negativity and can be used as a predictor of long PFS. Change of treatment strategy might be essential for patients with MRD positivity and high LMR at MRD assessment due to their short PFS.
    35 schema:genre article
    36 schema:isAccessibleForFree false
    37 schema:isPartOf N5d90bcee8fb74b689f5cb2239fd6a4f6
    38 N7bf6a2850b614c00989020a749f1d025
    39 sg:journal.1076985
    40 schema:keywords LMR
    41 MRD assessment
    42 MRD negativity
    43 MRD positivity
    44 MRD-negative patients
    45 MRD-positive patients
    46 PFS
    47 addition
    48 analysis
    49 assessment
    50 autologous stem cell transplantation
    51 cell transplantation
    52 changes
    53 chemotherapy
    54 clinical impact
    55 clinical significance
    56 complete response
    57 conclusion
    58 disease
    59 factors
    60 flowcytometry
    61 follow
    62 high LMR
    63 immunological status
    64 impact
    65 longer PFS
    66 low LMR
    67 lymphocytes
    68 markers
    69 median follow
    70 minimal residual disease
    71 monocyte ratio
    72 months
    73 multicolor flowcytometry
    74 multiple myeloma
    75 multiple myeloma patients
    76 myeloma
    77 myeloma patients
    78 negative minimal residual disease
    79 negativity
    80 patient's immunological status
    81 patients
    82 positivity
    83 predictors
    84 prognostic factors
    85 ratio
    86 residual disease
    87 response
    88 retrospective analysis
    89 shorter PFS
    90 significance
    91 single-center retrospective analysis
    92 status
    93 stem cell transplantation
    94 strategies
    95 study
    96 surrogate marker
    97 survival
    98 time
    99 transplantation
    100 treatment
    101 treatment strategies
    102 schema:name Clinical significance of the lymphocyte-to-monocyte ratio in multiple myeloma patients with negative minimal residual disease: a single-center retrospective analysis
    103 schema:pagination 599-607
    104 schema:productId N0c70518fd2294c2b9057e34717a4faf9
    105 N3259719f28bc4b5dad58e90c7800ec66
    106 Na9f2042e34304a8c8d83613a84d782a1
    107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1140125322
    108 https://doi.org/10.1007/s12185-021-03201-y
    109 schema:sdDatePublished 2022-08-04T17:09
    110 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    111 schema:sdPublisher N3fcac1bf954c4ac2ad3dfe81663c1407
    112 schema:url https://doi.org/10.1007/s12185-021-03201-y
    113 sgo:license sg:explorer/license/
    114 sgo:sdDataset articles
    115 rdf:type schema:ScholarlyArticle
    116 N0422762378e349a688beb000b8b34413 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    117 schema:name Leukocyte Count
    118 rdf:type schema:DefinedTerm
    119 N07738998501444cfb01254d0e0bd8727 rdf:first sg:person.015357612447.65
    120 rdf:rest Nde9dc2dac9034f06b7bb9f4fc73f16ec
    121 N0c70518fd2294c2b9057e34717a4faf9 schema:name doi
    122 schema:value 10.1007/s12185-021-03201-y
    123 rdf:type schema:PropertyValue
    124 N1bf95e64d8204a04a1aa1dea5417e9f0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    125 schema:name Disease Susceptibility
    126 rdf:type schema:DefinedTerm
    127 N1e997e9cfe1f43319553e70c9c7bddab rdf:first sg:person.016103216547.04
    128 rdf:rest Nd4ef4f462aa04d9c96ce6bb42a1f0dfc
    129 N30ac29c02c504fb09d31a1d2bd365313 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    130 schema:name Aged
    131 rdf:type schema:DefinedTerm
    132 N3259719f28bc4b5dad58e90c7800ec66 schema:name pubmed_id
    133 schema:value 34339005
    134 rdf:type schema:PropertyValue
    135 N3fcac1bf954c4ac2ad3dfe81663c1407 schema:name Springer Nature - SN SciGraph project
    136 rdf:type schema:Organization
    137 N459b43d041574207b7d658167377e51f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    138 schema:name Lymphocytes
    139 rdf:type schema:DefinedTerm
    140 N48bf56c423844ec88d897fcbe8fb46f9 rdf:first sg:person.01237063604.97
    141 rdf:rest Nd4632ce36cf846328db63452e565ede4
    142 N4d79d4832993471793d34ebb86178186 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    143 schema:name Middle Aged
    144 rdf:type schema:DefinedTerm
    145 N59898e3769fa4a1a847f32726181f482 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    146 schema:name Lymphocyte Count
    147 rdf:type schema:DefinedTerm
    148 N5d90bcee8fb74b689f5cb2239fd6a4f6 schema:issueNumber 5
    149 rdf:type schema:PublicationIssue
    150 N6698efdd38bd404082d1838481c551d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    151 schema:name Prognosis
    152 rdf:type schema:DefinedTerm
    153 N7bf6a2850b614c00989020a749f1d025 schema:volumeNumber 114
    154 rdf:type schema:PublicationVolume
    155 N952a0a32533747f6814ffe7ac4cf99ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    156 schema:name Biomarkers, Tumor
    157 rdf:type schema:DefinedTerm
    158 Na9f2042e34304a8c8d83613a84d782a1 schema:name dimensions_id
    159 schema:value pub.1140125322
    160 rdf:type schema:PropertyValue
    161 Nac60dfc9ab0b4d518eda7d88dc1d75a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    162 schema:name Neoplasm, Residual
    163 rdf:type schema:DefinedTerm
    164 Nae4bfc3aefe9435ba634236a655f19ec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    165 schema:name Female
    166 rdf:type schema:DefinedTerm
    167 Nb0f1ba2ee60b41e1b9550d3135c10afb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    168 schema:name Multiple Myeloma
    169 rdf:type schema:DefinedTerm
    170 Nbf7186c6356b441290d8f6903a24b4c3 rdf:first sg:person.01265010246.42
    171 rdf:rest rdf:nil
    172 Nc1b92b98958c4ffd9a3db28f8e0b38c1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    173 schema:name Disease Management
    174 rdf:type schema:DefinedTerm
    175 Nc2b4c2585d9b437caa2f4ab8124bb243 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    176 schema:name Retrospective Studies
    177 rdf:type schema:DefinedTerm
    178 Nc59b5a7bbeed49ea95efaa9e5cbadb36 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    179 schema:name Humans
    180 rdf:type schema:DefinedTerm
    181 Nc8ff6521558b48549b524d8f27542b0e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    182 schema:name Aged, 80 and over
    183 rdf:type schema:DefinedTerm
    184 Nca8d03478a8a4a0daa0cb3242d1396b6 rdf:first sg:person.011347513173.04
    185 rdf:rest N1e997e9cfe1f43319553e70c9c7bddab
    186 Nd4632ce36cf846328db63452e565ede4 rdf:first sg:person.01016710710.32
    187 rdf:rest N07738998501444cfb01254d0e0bd8727
    188 Nd4ef4f462aa04d9c96ce6bb42a1f0dfc rdf:first sg:person.01065024110.36
    189 rdf:rest Nbf7186c6356b441290d8f6903a24b4c3
    190 Nde9dc2dac9034f06b7bb9f4fc73f16ec rdf:first sg:person.014735732441.34
    191 rdf:rest Nca8d03478a8a4a0daa0cb3242d1396b6
    192 Nf1b4b763bb2b4c1bb3742b5be5004e13 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    193 schema:name Male
    194 rdf:type schema:DefinedTerm
    195 Nf32f5661ed164a6daf5fe1a761ba8c20 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    196 schema:name Monocytes
    197 rdf:type schema:DefinedTerm
    198 Nfc3d2fb4bc3243d7af0355526f48fea7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    199 schema:name Biomarkers
    200 rdf:type schema:DefinedTerm
    201 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    202 schema:name Medical and Health Sciences
    203 rdf:type schema:DefinedTerm
    204 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    205 schema:name Clinical Sciences
    206 rdf:type schema:DefinedTerm
    207 sg:journal.1076985 schema:issn 0925-5710
    208 1865-3774
    209 schema:name International Journal of Hematology
    210 schema:publisher Springer Nature
    211 rdf:type schema:Periodical
    212 sg:person.01016710710.32 schema:affiliation grid-institutes:grid.411898.d
    213 schema:familyName Nishiwaki
    214 schema:givenName Kaichi
    215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01016710710.32
    216 rdf:type schema:Person
    217 sg:person.01065024110.36 schema:affiliation grid-institutes:grid.411898.d
    218 schema:familyName Masuoka
    219 schema:givenName Hidekazu
    220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065024110.36
    221 rdf:type schema:Person
    222 sg:person.011347513173.04 schema:affiliation grid-institutes:grid.411898.d
    223 schema:familyName Fukushima
    224 schema:givenName Ryoko
    225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011347513173.04
    226 rdf:type schema:Person
    227 sg:person.01237063604.97 schema:affiliation grid-institutes:grid.411898.d
    228 schema:familyName Suzuki
    229 schema:givenName Kazuhito
    230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01237063604.97
    231 rdf:type schema:Person
    232 sg:person.01265010246.42 schema:affiliation grid-institutes:grid.411898.d
    233 schema:familyName Yano
    234 schema:givenName Shingo
    235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01265010246.42
    236 rdf:type schema:Person
    237 sg:person.014735732441.34 schema:affiliation grid-institutes:grid.411898.d
    238 schema:familyName Katori
    239 schema:givenName Mitsuji
    240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014735732441.34
    241 rdf:type schema:Person
    242 sg:person.015357612447.65 schema:affiliation grid-institutes:grid.411898.d
    243 schema:familyName Nagao
    244 schema:givenName Riku
    245 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015357612447.65
    246 rdf:type schema:Person
    247 sg:person.016103216547.04 schema:affiliation grid-institutes:grid.411898.d
    248 schema:familyName Hattori
    249 schema:givenName Daiki
    250 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016103216547.04
    251 rdf:type schema:Person
    252 sg:pub.10.1007/s11899-021-00633-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1137751851
    253 https://doi.org/10.1007/s11899-021-00633-5
    254 rdf:type schema:CreativeWork
    255 sg:pub.10.1007/s12185-019-02615-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1112212201
    256 https://doi.org/10.1007/s12185-019-02615-z
    257 rdf:type schema:CreativeWork
    258 sg:pub.10.1038/bcj.2017.60 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090295330
    259 https://doi.org/10.1038/bcj.2017.60
    260 rdf:type schema:CreativeWork
    261 sg:pub.10.1038/bmt.2012.244 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028358194
    262 https://doi.org/10.1038/bmt.2012.244
    263 rdf:type schema:CreativeWork
    264 sg:pub.10.1038/leu.2010.320 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024484528
    265 https://doi.org/10.1038/leu.2010.320
    266 rdf:type schema:CreativeWork
    267 sg:pub.10.1038/nri1886 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004152575
    268 https://doi.org/10.1038/nri1886
    269 rdf:type schema:CreativeWork
    270 sg:pub.10.1038/s41375-018-0163-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1104990592
    271 https://doi.org/10.1038/s41375-018-0163-4
    272 rdf:type schema:CreativeWork
    273 sg:pub.10.1038/s41408-017-0019-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1099676148
    274 https://doi.org/10.1038/s41408-017-0019-6
    275 rdf:type schema:CreativeWork
    276 sg:pub.10.1038/s41409-019-0681-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1121007421
    277 https://doi.org/10.1038/s41409-019-0681-3
    278 rdf:type schema:CreativeWork
    279 sg:pub.10.1038/sj.bmt.1705373 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047732682
    280 https://doi.org/10.1038/sj.bmt.1705373
    281 rdf:type schema:CreativeWork
    282 grid-institutes:grid.411898.d schema:alternateName The Jikei University School of Medicine, Tokyo, Japan
    283 schema:name Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University Kashiwa Hospital, 163-1 Kashiwa-shita, 277-8567, Kashiwa, Chiba, Japan
    284 The Jikei University School of Medicine, Tokyo, Japan
    285 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...